Atumelnant - Misplaced Pages

This is the current revision of this page, as edited by AlyInWikiWonderland (talk | contribs) at 07:18, 9 January 2025 (No longer an orphan.). The present address (URL) is a permanent link to this version.

Revision as of 07:18, 9 January 2025 by AlyInWikiWonderland (talk | contribs) (No longer an orphan.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Pharmaceutical compound

Atumelnant
Clinical data

Other names	CRN04894
Identifiers
IUPAC name N-octan-3-yl]-6-(2-ethoxyphenyl)-3-piperazin-1-yl]pyridine-2-carboxamide
CAS Number	2392970-97-5
PubChem CID	146361282
IUPHAR/BPS	13339
UNII	NR57FH6U1N
Chemical and physical data
Formula	C₃₃H₄₂F₃N₅O₃
Molar mass	613.726 g·mol
3D model (JSmol)	Interactive image
SMILES CC1CN(CCN1C2=C(N=C(C=C2)C3=CC=CC=C3OCC)C(=O)N4CN5CCC4CC5)C(=O)C6(CCC6)C(F)(F)F
InChI InChI=InChI=1S/C33H42F3N5O3/c1-3-23-20-40(31(43)32(14-7-15-32)33(34,35)36)18-19-41(23)27-11-10-25(24-8-5-6-9-28(24)44-4-2)37-29(27)30(42)38-26-21-39-16-12-22(26)13-17-39/h5-6,8-11,22-23,26H,3-4,7,12-21H2,1-2H3,(H,38,42)/t23-,26-/m1/s1 Key:QJRFBKYETDVAJQ-ZEQKJWHPSA-N

Atumelnant (developmental code name CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands. Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.

References

"Atumelnant (CRN04894)". crinetics.com. 14 August 2020.
Varlamov EV, Gheorghiu ML, Fleseriu M (December 2024). "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy. doi:10.1080/14656566.2024.2446625. PMID 39718553.

v t e Melanocortin receptor modulators
MC₁	Agonists: ACTH (corticotropin) Afamelanotide (melanotan I) BMS-470539 Bremelanotide HS-014 HS-024 MSH (α, β, γ) Melanotan II Modimelanotide PL-8177 SHU-8914 SHU-9005 SHU-9119 SNAP-7941 Antagonists: ASIP
MC₂	Agonists: ACTH (corticotropin) Alsactide Codactide Giractide Norleusactide (pentacosactride) Seractide Tetracosactide (tetracosactrin, cosyntropin) Tosactide (octacosactrin) Tricosactide Tridecactide Antagonists: Atumelnant
MC₃	Agonists: ACTH (corticotropin) Afamelanotide (melanotan I) Bremelanotide MSH (α, β, γ) Melanotan II Modimelanotide PG-931 Antagonists: AGRP ASIP HS-014 ML-00253764 PG-106 SHU-8914 SHU-9005 SHU-9119
MC₄	Agonists: ACTH (corticotropin) Afamelanotide (melanotan I) AZD2820 BIM-22493 Bremelanotide LY-2112688 MSH (α, β, γ) Melanotan II MK-0493 Modimelanotide PF-00446687 PG-931 PL-6983 Ro 27-3225 Setmelanotide THIQ Antagonists: AGRP ASIP HS-014 HS-024 HS-131 JKC-363 MCL-0020 MCL-0042 MCL-0129 ML-00253764 MPB-10 SHU-8914 SHU-9005 SHU-9119 Unknown: Semax
MC₅	Agonists: ACTH (corticotropin) Afamelanotide (melanotan I) Bremelanotide HS-014 HS-024 MSH (α, β, γ) Melanotan II Modimelanotide SHU-8914 SHU-9005 SHU-9119 Antagonists: ASIP ML-00253764 Unknown: Semax
Unsorted	Agonists: Alsactide Codactide Dersimelagon Giractide Norleusactide (pentacosactride) Seractide Tetracosactide (tetracosactrin, cosyntropin) Tosactide (octacosactrin) Tricosactide Tridecactide
Others	Propeptides: Lipotropin (β, γ) N-POMC (NPP, pro-γ-MSH) Proopiomelanocortin (POMC)

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: